KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EBIT (2016 - 2025)

Rigel Pharmaceuticals has reported EBIT over the past 16 years, most recently at $23.2 million for Q4 2025.

  • Quarterly results put EBIT at $23.2 million for Q4 2025, up 39.12% from a year ago — trailing twelve months through Dec 2025 was $125.5 million (up 418.63% YoY), and the annual figure for FY2025 was $125.5 million, up 418.63%.
  • EBIT for Q4 2025 was $23.2 million at Rigel Pharmaceuticals, down from $28.4 million in the prior quarter.
  • Over the last five years, EBIT for RIGL hit a ceiling of $61.1 million in Q2 2025 and a floor of -$26.3 million in Q1 2022.
  • Median EBIT over the past 5 years was -$2.0 million (2023), compared with a mean of $3.1 million.
  • Biggest five-year swings in EBIT: plummeted 162.89% in 2022 and later soared 13569.57% in 2025.
  • Rigel Pharmaceuticals' EBIT stood at -$21.4 million in 2021, then soared by 109.71% to $2.1 million in 2022, then dropped by 5.44% to $2.0 million in 2023, then soared by 747.15% to $16.7 million in 2024, then soared by 39.12% to $23.2 million in 2025.
  • The last three reported values for EBIT were $23.2 million (Q4 2025), $28.4 million (Q3 2025), and $61.1 million (Q2 2025) per Business Quant data.